Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1979 1
1981 1
1982 1
1985 1
1986 2
1987 1
1989 1
1994 2
1995 1
1997 2
2001 1
2002 4
2003 6
2004 10
2005 6
2006 8
2007 4
2008 6
2009 5
2010 6
2011 8
2012 20
2013 13
2014 25
2015 26
2016 32
2017 23
2018 24
2019 21
2020 12
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 24035293

247 results
Results by year
Filters applied: . Clear all
Page 1
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
Lorente Fernández L, Monte Boquet E, Pérez-Miralles F, Gil Gómez I, Escutia Roig M, Boscá Blasco I, Poveda Andrés JL, Casanova-Estruch B. Lorente Fernández L, et al. Neurologia. 2014 Jun;29(5):257-60. doi: 10.1016/j.nrl.2013.06.014. Epub 2013 Sep 10. Neurologia. 2014. PMID: 24035293 Free article. English, Spanish.
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J, Feneberg W, Meier M, Pöllmann W. Koehler J, et al. Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460. Epub 2014 Jan 23. Int J Neurosci. 2014. PMID: 24392812
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ, Nurmikko TJ, Young CA. Rog DJ, et al. Clin Ther. 2007 Sep;29(9):2068-79. doi: 10.1016/j.clinthera.2007.09.013. Clin Ther. 2007. PMID: 18035205 Clinical Trial.
Sativex for the management of multiple sclerosis symptoms.
Perras C. Perras C. Issues Emerg Health Technol. 2005 Sep;(72):1-4. Issues Emerg Health Technol. 2005. PMID: 16317825
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C. Markovà J, et al. Int J Neurosci. 2019 Feb;129(2):119-128. doi: 10.1080/00207454.2018.1481066. Epub 2018 Sep 13. Int J Neurosci. 2019. PMID: 29792372 Clinical Trial.
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R. Arroyo González R. Expert Rev Neurother. 2018 Oct;18(10):785-791. doi: 10.1080/14737175.2018.1510772. Epub 2018 Sep 20. Expert Rev Neurother. 2018. PMID: 30235965 Review.
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Lus G, Cantello R, Danni MC, Rini A, Sarchielli P, Tassinari T, Signoriello E. Lus G, et al. Neurodegener Dis Manag. 2018 Apr;8(2):105-113. doi: 10.2217/nmt-2017-0056. Epub 2018 Apr 23. Neurodegener Dis Manag. 2018. PMID: 29683408 Clinical Trial.
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Serpell MG, Notcutt W, Collin C. Serpell MG, et al. J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10. J Neurol. 2013. PMID: 22878432 Clinical Trial.
Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Ferrè L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, Colombo B, Keller Sarmiento IJ, Martinelli V, Leocani L, Martinelli Boneschi F, Comi G, Esposito F. Ferrè L, et al. Neurol Sci. 2016 Feb;37(2):235-42. doi: 10.1007/s10072-015-2392-x. Epub 2015 Oct 16. Neurol Sci. 2016. PMID: 26474875
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P, Trojano M. Vermersch P, et al. Eur Neurol. 2016;76(5-6):216-226. doi: 10.1159/000449413. Epub 2016 Oct 13. Eur Neurol. 2016. PMID: 27732980
247 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback